Germline Genetic Variants and Faliure of Acitve Sureveillance

Abbreviated Name: Catalona - Germline Variants

Protocol ID: 433

Lead Investigator: Lin UW, Daniel W. — University of Washington

Coordinating Investigator: Feng, Ziding — Fred Hutchinson Cancer Research Center

Involved Investigator Sites:

Lin UW, Daniel W. — University of Washington

Biomarker Name:

Design: No design specified.

Field(s) of Research: Genomics

Collaborative Group: Prostate and Urologic Cancers Research Group

Phased Status: 2

Abstract:

Study the impact of germline genetic variants on Active Surveillance (AS) failure. Information will help develop methods for identifying men with low-risk PC who can be managed safely with AS. This project is funded by the NCI (NIH/NCI P50 CA 090386), utilizing genotyping funded by a grant from the Center for Inherited Disease Research (CIDR) (X01HG009642). The inclusion of the Canary PASS samples and clinical data requested here is crucial for fulfilling the overall goals of the project that are: (1) reducing overtreatment of PC; (2) identifying new biomarkers for treatment decisions; and (3) identifying molecular targets for pharmaceutical manipulation and/or possibly providing clues for new PC prevention strategies. Taken together, these efforts will advance our fundamental understanding of germline genetic factors that influence PC aggressiveness.

Aims: Specific Aim 1: Designing custom content array and genotyping We will work closely with all collaborators and CIDR to incorporate the 10,000 custom content variants specific to PC on the Illumina Infinium Multi-Ethnic Array. All 5061 DNA samples from men with PC on AS will be sent to CIDR for genotyping. Specific Aim 2: Testing previously reported variants Here, we will test the association between AS and variants previously associated with PC susceptibility or aggressiveness from the literature, study collaborators, and other colleagues. Specific Aim 3: Evaluating associations with new variants In this aim we will test the associations between the genome-wide variants and AS.

Analytic Method:

Comments:

Biomarkers:

There are currently no biomarkers annotated for this protocol.

Datasets:

No datasets are currently associated with this protocol.